Metreleptin treatment of non-HIV lipodystrophy syndromes - 24/09/21
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Lipodystrophy syndromes (LS) constitute a group of rare diseases of the adipose tissue, characterized by a complete or selective deficiency of the fat mass. These disorders are associated with important insulin resistance, cardiovascular and metabolic comorbidities that impact patient's survival and quality of life. Management is challenging and includes diet, physical activity, and specific pharmacological treatment of LS-associated comorbidities. Because of a common pathophysiology involving decreased concentration of the adipokine leptin, efforts have been made to develop therapeutic strategies with leptin replacement therapy. Metreleptin, a recombinant human leptin analogue, has been proposed in hypoleptinemic patients since the beginning of 2000’s. The treatment leads to an improvement in metabolic parameters, more important in generalized than in partial LS forms. In this review, the current knowledge about the development of the drug, its outcomes in the treatment of lipodystrophic patients as well as the peculiarities of its use will be presented.
Le texte complet de cet article est disponible en PDF.Keywords : metreleptin, lipodystrophy syndromes, diabetes, dyslipidemia
Abbreviations : AGL, ALAT, ALP, ASAT, AgRP, CGL, FPLD, FSH, GGT, GL, GLP-1, HbA1c, HDLc, HIV, LH, LMNA, LDLc, LPL, LS, NPY, PCOS, PL, PPARG, SGLT2, TG
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?